Drug Profile


Latest Information Update: 17 Feb 2010

Price : $50

At a glance

  • Originator Sciele Pharma
  • Developer Shionogi Pharma
  • Class Antimigraines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 16 Jun 2006 First Horizon Pharmaceutical Corporation is now called Sciele Pharma
  • 23 Jun 2003 Phase-I clinical trials in Migraine in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top